Financial News
Latest News about DSNKY
Recent news which mentions DSNKY
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
April 08, 2024
From Benzinga
What's Going On With Pfizer Stock Today?
January 25, 2024
From Benzinga
From Benzinga
From Benzinga
From Motley Fool
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
September 22, 2023
From Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
September 11, 2023
From Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
July 21, 2023
From Benzinga
From Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
July 03, 2023
From Benzinga
Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
June 27, 2023
Tickers
DSNKY
From Benzinga
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
March 20, 2023
From Benzinga
First Republic Bank sinks on possible sale reports, and Credit Suisse’s stock boosted by central bank borrowing
March 16, 2023
From MarketWatch
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
March 06, 2023
From Benzinga
Is Gilead Sciences a Good Stock to Buy Now?
February 06, 2023
From Motley Fool
From Benzinga
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
December 19, 2022
From Benzinga
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
December 09, 2022
From Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
November 14, 2022
From Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
September 21, 2022
From Benzinga
Why MacroGenics Stock Sank Today
September 12, 2022
From Motley Fool
This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says
September 12, 2022
From Benzinga
3 Top Stocks to Invest In Right Now
August 16, 2022
From InvestorPlace
Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
August 15, 2022
From Benzinga
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
August 15, 2022
From Benzinga
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
August 12, 2022
From Benzinga
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
August 09, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.